Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

378
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
378
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

803
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
803
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

625
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
625
Depression: Overview01:18

Depression: Overview

369
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
369
An Overview of Psychoactive Drugs01:28

An Overview of Psychoactive Drugs

309
Psychoactive drugs impact brain function, influencing perception, mood, consciousness, cognition, and behavior. These substances are grouped based on their effects and the mechanisms by which they act.
Stimulants such as cocaine, amphetamines, and nicotine enhance brain activity, leading to increased alertness, attention, and energy. These drugs typically raise heart rate, blood pressure, and body temperature. While they can induce feelings of euphoria, their misuse can result in severe health...
309
Drug Therapy01:28

Drug Therapy

107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
107

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human brain changes after first psilocybin use.

Nature communications·2026
Same author

The global extent of the grassland biome and implications for the terrestrial carbon sink.

Nature ecology & evolution·2026
Same author

Prevalence of Sickle Cell Disease among Newborns in St Vincent and the Grenadines: A Retrospective Study.

The West Indian medical journal·2024
Same author

Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study.

Archives of suicide research : official journal of the International Academy for Suicide Research·2024
Same author

Psilocybin and Other Classic Psychedelics in Depression.

Current topics in behavioral neurosciences·2023
Same author

Canalization and plasticity in psychopathology.

Neuropharmacology·2022

Related Experiment Video

Updated: Sep 18, 2025

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

37.8K

Serotonergic psychedelics for depression: A comprehensive overview.

A M Wingert1, C Agnorelli1, J Peill1

  • 1Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine, Centre for Psychedelic Research, Imperial College London, London, United Kingdom.

International Review of Neurobiology
|June 20, 2025
PubMed
Summary
This summary is machine-generated.

Serotonin agonists like psilocybin show rapid antidepressant effects for major depressive disorder (MDD) and treatment-resistant depression (TRD). Clinical trials suggest these psychedelics offer a promising alternative to conventional treatments, despite integration challenges.

Keywords:
Clinical trialsDepressionMDDPsychedelicsTRD

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.9K
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.4K

Related Experiment Videos

Last Updated: Sep 18, 2025

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

37.8K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.9K
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.4K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Depressive disorders, including major depressive disorder (MDD) and treatment-resistant depression (TRD), represent a significant global health challenge.
  • Conventional pharmacotherapies often have limitations, particularly for treatment-resistant cases.

Purpose of the Study:

  • To review the antidepressant potential of psilocybin, DMT, ayahuasca, and 5-MeO-DMT based on clinical trial data.
  • To compare the efficacy of these serotonergic psychedelics with conventional treatments like SSRIs and ketamine.
  • To provide an overview of the potential neurobiological mechanisms underlying psychedelic-induced antidepressant effects.

Main Methods:

  • Review of modern clinical trial data on psilocybin, DMT, ayahuasca, and 5-MeO-DMT.
  • Comparative analysis of effect sizes between psychedelic treatments and conventional pharmacotherapies (SSRIs, ketamine).
  • Examination of safety data and pharmacological profiles of 5-HT₂A receptor agonists.

Main Results:

  • Phase I and II trials indicate that single-dose administration of psilocybin and other 5-HT₂A agonists can achieve rapid and sustained reductions in depressive symptoms.
  • Psychedelic treatments demonstrate favourable efficacy compared to SSRIs and ketamine.
  • Serotonergic psychedelics exhibit a distinct pharmacological profile and robust safety data.

Conclusions:

  • Psilocybin and related compounds show significant promise as novel antidepressants, particularly for patients with MDD and TRD unresponsive to standard treatments.
  • Psychedelic-assisted therapy offers a potentially effective alternative, though challenges related to resource intensity and specialized settings exist.
  • Regulatory advancements in countries like Australia, Switzerland, and Canada are beginning to facilitate clinical access for TRD.